Sunovion, the US subsidiary of Japanese drug maker Dainippon Sumitomo Pharma Co., will market Latuda to those patients and their physicians who are interested in a new treatment option for adults with schizophrenia.
SIGN IN WITH ONE OF YOUR SOCIAL ACCOUNTS
Sign in with your MMM account
Keep me signed in Forgot your password?
REGISTER FOR FREE WITH ONE OF YOUR SOCIAL ACCOUNTS
REGISTER FOR FREE WITH A MMM ACCOUNT
Enter your MMM registration email address to receive a password reset link.
ENTER NEW PASSWORD